Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUSNASDAQ:KDNYNASDAQ:ODTNASDAQ:OGINASDAQ:PRVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/AODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsOGIOrganigram Global$1.42+2.9%$1.31$0.85▼$2.08$191.53M1.36657,847 shs546,098 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%KDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%OGIOrganigram Global0.00%+5.19%+5.97%+49.38%-10.69%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global0.6586 of 5 stars0.01.00.00.01.10.02.5PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/AKDNYChinook Therapeutics 0.00N/AN/AN/AODTOdonate Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/APRVBProvention Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AKDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AOGIOrganigram Global$117.47M1.62N/AN/A$2.07 per share0.69PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AKDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/AODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/AOGIOrganigram Global-$33.39M$0.1014.20N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30KDNYChinook TherapeuticsN/A5.825.82ODTOdonate TherapeuticsN/AN/AN/AOGIOrganigram GlobalN/A3.421.90PRVBProvention Bio0.191.931.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/AKDNYChinook Therapeutics95.15%ODTOdonate TherapeuticsN/AOGIOrganigram Global34.63%PRVBProvention Bio37.39%Insider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%KDNYChinook Therapeutics16.79%ODTOdonate Therapeutics48.90%OGIOrganigram Global0.09%PRVBProvention Bio13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableOGIOrganigram Global860133.94 million133.82 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableOGI, PRVB, KDNY, AKUS, and ODT HeadlinesRecent News About These CompaniesProvention finally gets FDA nod for type 1 diabetes drug teplizumabMarch 9, 2025 | pharmaphorum.comPFDA rejects Provention's type 1 diabetes drug teplizumabNovember 19, 2024 | pharmaphorum.comPKimber Creek FordAugust 2, 2024 | cars.comCAnn Tricklebank Biography & MoviesMay 25, 2024 | tribute.caTVOA NewsMay 22, 2024 | voanews.comVTopic - Cumberland Valley School DistrictMay 5, 2024 | washingtontimes.comWMacrogenics Inc MGNXDecember 29, 2023 | morningstar.comMAnd for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside DiabetesNovember 13, 2023 | medpagetoday.comMTeplizumab and β-Cell Function in Newly Diagnosed Type 1 DiabetesOctober 24, 2023 | nejm.orgNFDA sets August decision date for Provention's type 1 diabetes drugJuly 23, 2023 | pharmaphorum.comPLarry Pine Biography & MoviesJune 27, 2023 | tribute.caTSanofi/Provention: innovative diabetes drug is a good fitMay 1, 2023 | finance.yahoo.comThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 29, 2023 | finance.yahoo.comSanofi completes Provention Bio acquisitionApril 28, 2023 | seekingalpha.comSanofi concludes acquisition of Provention BioApril 28, 2023 | medicaldialogues.inMSanofi completes acquisition of Provention Bio, Inc.April 28, 2023 | pharmiweb.comPEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finance.yahoo.comSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 27, 2023 | finanznachrichten.deProvention Bio gains after HSR waiting period for Sanofi deal expiredApril 26, 2023 | seekingalpha.comPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 26, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityOGI, PRVB, KDNY, AKUS, and ODT Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Chinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Odonate Therapeutics NASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Organigram Global NASDAQ:OGI$1.42 +0.04 (+2.90%) Closing price 07/3/2025 03:34 PM EasternExtended Trading$1.43 +0.01 (+0.70%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
